Preliminary results show targeted approach reduces toxicity to organs at risk
NASHUA, NH and DENVER, CO (Booth #6010) July 27, 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present clinical data supporting use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of endometrial cancer at the American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition in Denver, Colorado from July 30 to August 3, 2017. iCAD will also showcase its multi-platform Xoft System and related suite of products at its booth (#6010) during the meeting.
“These preliminary data add to a growing body of clinical evidence demonstrating promising results in support of the clinical effectiveness of the Xoft System for patients and clinicians,” said Ken Ferry, CEO of iCAD. “The results support the proven benefits of the Xoft System and are another milestone in our ongoing commitment to providing the most innovative and advanced technologies in cancer treatment in the years ahead.”
Researchers from Miguel Servet University Hospital in Zaragoza, Spain will present preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by treatment with Ir-192 or Co-60 sources.
“By precisely targeting cancer cells and sparing surrounding healthy tissue and organs, the Xoft System can successfully treat endometrial cancer while reducing the risk of exposure to surrounding tissue,” said Sergio Lozares, MD, Medical Physicist at Miguel Servet University Hospital. “We are encouraged by these early results demonstrating that the Xoft System can be a clinically valuable treatment option for appropriate patients.”
The results will be presented in a poster presentation during the meeting, the details of which are as follows:
Title: Dosimetric Comparison of Brachytherapy Sources for High Dose Rate Treatment of Endometrial Cancer: Electronic Brachytherapy, 192Ir and 60Co Sources
Date: Sunday, July 30, 2017
Time: 3:00-6:00 pm MT
Location: Exhibit Hall
Presentation Number: SU-I-GPD-T-20
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
Bob Yedid, (646)-597-6989
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881